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Purpose: Long-acting β2-agonists (LABAs) have demonstrated efficacy in patients with COPD 
in clinical trials. The purpose of this study was to assess the comparative efficacy of all available 
dosages of all LABA monotherapies using a network meta-analysis.
Methods: A systematic literature review identified 33 randomized controlled trials of LABA 
monotherapies (salmeterol 50 μg twice daily [BID]; formoterol 12 μg BID; indacaterol 75, 150, 
and 300 μg once daily [OD]; olodaterol 5 and 10 μg OD, and vilanterol 25 μg OD). Clinical effi-
cacy was evaluated at 12 and 24 weeks in terms of trough forced expiratory volume in 1 second 
(FEV
1
), transition dyspnea index focal score, St George’s Respiratory Questionnaire total score, 
and rate of COPD exacerbations. The relative effectiveness of all LABA monotherapies was 
estimated by Bayesian network meta-analysis.
Results: At 12 and 24 weeks, indacaterol 300 and 150 μg OD were associated with statistically 
significant improvement in trough FEV
1
 compared to all other LABA monotherapies; vilanterol 
25 μg OD was superior to formoterol 12 μg BID. At 12 weeks, indacaterol 75 μg OD was 
associated with significant improvement in trough FEV
1
 compared to formoterol 12 μg BID 
and olodaterol (5 and 10 μg OD); salmeterol 50 μg BID was superior to formoterol 12 μg BID 
and olodaterol 5 μg OD. Indacaterol 300 μg OD was also associated with significant improve-
ment in transition dyspnea index focal score compared to all other LABAs at 12 or 24 weeks. 
Indacaterol 150 μg OD had significantly better results in exacerbation rates than olodaterol 
5 μg and olodaterol 10 μg OD.
Conclusion: Indacaterol 300 μg, followed by 150 and 75 μg, were the most effective LABA 
monotherapies for moderate to severe COPD.
Keywords: COPD, long-acting β2-agonists, network meta-analysis, systematic literature 
review, indacaterol
Introduction
COPD is a chronic, progressive disease of the lung characterized by poor airflow, 
shortness of breath, and cough, and leads to long-term decline in lung function.1 
Approximately 5% of the world population (~329 million people) are affected by 
COPD,2 which is correlated with tobacco use,3 older age,4 pollution,5,6 and genetics.1,7,8 
This disease is a major cause of morbidity and mortality, and was responsible for 3 
million deaths globally as estimated by the World Health Organization in 2012.1,6,9,10 
The World Health Organization also estimates that over one-third of premature deaths 
attributable to COPD in low- and middle-income countries are due to indoor exposure 
to smoke.11 In addition, COPD patients may experience frequent exacerbations, respi-
ratory infections, and COPD-related hospitalizations that contribute to a substantial 
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social and economic burden,12 accounting for an estimated 
$18 billion in direct medical costs in the USA and ~€38.7 
billion in the European Union.10
There is no cure for COPD, but appropriate pharmaco-
logic therapy is critical in reducing the frequency and severity 
of symptoms. Bronchodilators, which alter airway smooth 
muscle tone, are central to the management of COPD symp-
toms. Long-acting β2-agonists (LABAs) and long-acting 
muscarinic antagonists (LAMAs) are two commonly used 
bronchodilators.1 LABA monotherapy is contraindicated for 
patients with asthma, due to an increased risk of the exacer-
bation of asthma symptoms.13
A variety of LABAs with different durations of action, 
routes of administration, delivery devices, and associated rates 
of exacerbation, breathlessness, and bronchodilator effects 
are currently available.1,14 Commonly used LABAs include 
twice-daily (BID) salmeterol 50 μg and formoterol 12 μg, 
which have a duration of action of 12 hours. Newer agents 
such as indacaterol 75/150/300 μg,15 olodaterol 5/10 μg,16 and 
vilanterol 25 μg17 are given once daily (OD) with a duration 
of action of 24 hours. (Indacaterol 150 and 300 μg, olodaterol 
10 μg, and vilanterol 25 μg are not commercially available 
in the USA.) Given the variety of available LABAs for the 
treatment of COPD, physicians are faced with the difficulty 
of choosing the LABA with optimal efficacy. Randomized 
controlled trials (RCTs) have evaluated the efficacy of 
long-acting LABA monotherapies against placebo and/or 
short-acting LABAs. In RCTs, indacaterol was found to have 
a significantly greater bronchodilator effect than placebo, 
formoterol 12 μg BID, and salmeterol 50 μg BID.15,18,19 In 
addition, olodaterol (5/10 μg) was superior to placebo and 
formoterol 12 μg BID,16,20 and vilanterol 25 μg OD was 
superior to placebo.17,21,22 In addition, several earlier network 
meta-analyses (NMAs) have indirectly compared the efficacy 
among a limited number of LABAs/LAMAs.23,24 In 2013, 
Cope et al compared 40 RCTs in a Bayesian meta-analysis 
and found that indacaterol (150/300 μg), glycopyrronium 
50 μg, and tiotropium 5 μg were superior to other LABAs, 
with indacaterol dominant in forced expiratory volume in 
1 second (FEV
1
) and St George’s Respiratory Question-
naire (SGRQ) score improvement.23 In 2014, Roskell et al 
compared olodaterol 5 μg and indacaterol (75/150 μg) in a 
meta-analysis of 18 RCTs, and found no significant differ-
ences in their primary analysis.24
However, studies evaluating the comparative efficacy of 
all currently available LABAs, including the newer agents 
in different doses, have not been conducted. Thus, this study 
aimed to evaluate the comparative efficacy of all available 
LABA monotherapy inhalers trialed in patients with moder-
ate to severe COPD using an NMA. LABAs included in the 
network were salmeterol 50 μg BID (inhalation powder), 
formoterol 12 μg BID (inhalation powder), indacaterol 
75/150/300 μg OD (inhalation powder), olodaterol 5 and 
10 μg OD (inhalation spray), and vilanterol 25 μg OD 
(inhalation powder). (Indacaterol 150 and 300 μg, olodaterol 
10 μg, and vilanterol 25 μg are not commercially available 
in the USA.) The efficacy of these LABAs was evaluated 
using the following outcomes: 1) trough FEV
1
 at 12 and 
24 weeks; 2) transition dyspnea index (TDI) focal score at 
12 and 24 weeks; 3) SGRQ total score at 12 and 24 weeks; 
and 4) rate of exacerbation.
Methods
Study identification and selection
A systematic literature review was conducted to update an 
earlier systematic review completed in 2013.23 The updated 
search was performed in MEDLINE and MEDLINE-In-
Process, EMBASE, and Cochrane databases through Ovid 
for RCTs evaluating the efficacy of LABA monotherapies 
(indacaterol [indacaterol inhalation powder], salmeterol [sal-
meterol xinafoate inhalation powder], olodaterol [olodaterol 
inhalation spray], vilanterol [vilanterol inhalation powder], 
and formoterol [formoterol inhalation powder]) trialed in 
patients with moderate to severe COPD. The studies identi-
fied from the updated search spanned from January 1, 2013 
to March 24, 2015, while the earlier search had extended 
back to 1989.23 Full-text terms and common abbreviations, 
listed in the Supplementary material, were used for the search 
strategy. Eligible studies from both the earlier and updated 
systematic literature reviews were included in the current 
meta-analysis.
All articles identified in the initial database search were 
screened for relevance based on title, abstract, and full-text 
articles. RCTs that reported at least one of the outcomes of 
interest for the targeted interventions among adults with 
moderate to severe COPD were selected. To be included 
into the network, trials were further required to include a 
comparison of at least two of the interventions of interest or 
one of the above interventions against placebo. The selection 
criteria for the study population, interventions, comparators, 
and outcomes are detailed in Table 1. The screening process 
was independently conducted by and reconciled between 
two researchers, and in the event of a discrepancy, a third 
researcher was consulted.
Trials were excluded if they were duplications, confer-
ence abstracts only, ,12 weeks in duration, or if the patient 
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population, trial design, intervention, comparator, or out-
comes did not meet the inclusion criteria (Table 1).
Outcome measures
Six continuous outcomes and one rate outcome were included 
in the NMA. Continuous outcomes included trough FEV
1
, 
TDI focal score, and SGRQ total score at 12 and 24 weeks. 
In the absence of 12- and 24-week data, data within a 
2-week range for each time point of interest were allowed 
(ie, between 10 and 14 weeks for the 12-week time point 
and between 22 and 26 weeks for the 6-month time point). 
Differences between the least square mean at follow-up or 
the change from baseline for the active treatment versus 
the comparator were used for the network analysis. To be 
included in the network, outcomes had to be reported for 
each treatment group in a clear manner to allow reliable 
estimation of the treatment differences and their associated 
standard errors.
Rates of exacerbation were compared between the treat-
ment groups at the end of trial follow-up. To be included in 
the network, this outcome had to be reported as the number 
of events of exacerbation with the total patient years of 
follow-up. If such event rates were not available, the rates 
were then calculated as the number of total events divided by 
the total patient-years which allowed the rates of exacerba-
tions accumulated over differing periods of follow-up to 
be compared (assuming the risk of exacerbations remained 
constant over time). Severity of the exacerbation could not be 
incorporated into the analysis due to lack of granular severity 
reporting within the trials.
Network meta-analyses
NMA combines data from several different randomized 
comparisons of different treatments to deliver an internally 
consistent set of estimates while respecting the randomiza-
tion within each trial. This NMA was carried out within a 
generalized linear model framework with a link function 
which specified the relationship between the outcome and 
the model coefficients to be estimated. When an outcome was 
continuous, such as trough FEV
1
, the likelihood was modeled 
as normal. When the outcome was an event rate, such as the 
per patient-year event rate of exacerbation, the likelihood 
was modeled as Poisson.25,26 Random effect models were 
utilized for this analysis. The estimation was performed under 
a Bayesian context, using noninformative prior distributions 
for parameters. The model was evaluated using the Deviance 
Information Criterion, a measure which combines model fit 
and complexity. This analysis was estimated using a Bayesian 
Markov Chain Monte Carlo model. All analyses were 
implemented using the statistical software R (v3.2.2; Ross 
Ihaka and Robert Gentleman, open source) and OpenBUGS 
(v3.2.3; OpenBUGS Foundation).
Sensitivity analyses
Because trough FEV
1
 was the primary efficacy outcome of 
the majority of the RCTs, sensitivity analyses were conducted 
for the FEV
1
 12- and 24-week outcomes to test the robust-
ness of the NMA results. Specifically, because concomitant 
medications and COPD severity are potential treatment effect 
modifiers, the sensitivity analyses included: 1) a subset of 
trials with no concomitant LAMA usage (all trials which 
permitted concomitant usage were excluded); 2) a meta-
regression adjusting for disease severity (adjusting for the 
percent of patients with severe/very severe COPD); and 
3) a meta-regression adjusting for inhaled corticosteroid 
(ICS) use (adjusting for the percent of patients with ICS use 
within each trial).
Results
Evidence base
The updated systematic review identified 916,17,20–22,27–30 full-
text articles detailing 12 RCTs that met the inclusion criteria 
(Figure 1). These were pooled with 21 LABA monotherapy 
RCTs identified in the previous search,15,18,19,31–48 resulting in 
a total of 33 RCTs included in the NMA. A list of included 
studies and details of the systematic literature search can be 
found in Figure 1, and the details of each study’s own inclu-
sion criteria are listed in Table S1. All studies were double-
blind, multicenter RCTs (Figure 2), ranging from 12 weeks 
Table 1 Study selection criteria for inclusion in the network meta-
analysis
Characteristic Inclusion criteria
Population adults with moderate to severe COPD
Interventions Monotherapies:
Indacaterol (75 μg OD or 150 μg OD or  
300 μg OD)
Olodaterol (5 μg OD or 10 μg OD)
Vilanterol (25 μg OD)
salmeterol (50 μg BID)
Formoterol (12 μg BID)
Comparators Any of the interventions listed above or placebo
Outcomes Trough FEV1 at 12 and 24 weeks
sgrQ total score at 12 and 24 weeks
TDI focal score at 12 and 24 weeks
Rate of exacerbation (trial duration)
Study design Randomized controlled clinical study 
Abbreviations: BID, twice daily; COPD, Chronic Obstructive Pulmonary Disease; 
FeV1, forced expiratory volume in 1 second; OD, once daily; SGRQ, St George’s 
Respiratory Questionnaire; TDI, transition dyspnea index.
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Figure 1 PRISMA diagram showing selection of LABA monotherapy trials.
Notes: aSearch was performed for abstracts published between January 1, 2013 and March 24, 2015. bPrior search was performed for abstracts published between 1989 
and January 1, 2013.
Abbreviations: LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; RCT, randomized controlled trial.
to 3 years in duration. All studies were placebo controlled, 
with the exception of one head-to-head study which com-
pared the efficacy of indacaterol 150 μg OD to salmeterol 
50 μg BID.19 The studies were predominantly conducted in 
multiple countries simultaneously, although four were limited 
to the USA32,35,36,44 and one was limited to the Netherlands.40 
The majority of the studies were conducted in patients over 
the age of 40 with a smoking history of $10 pack-years and 
predicted FEV
1
 of #80%. Each trial predominantly enrolled 
male patients, and the mean age was .60 years in all trials. 
The percentage of ICS use, current smokers, and patients 
with severe or very severe COPD varied among studies. 
Patient characteristics of the selected trials are further detailed 
in Table S2.
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Network meta-analysis
The 33 RCTs were synthesized in the NMA; a network 
diagram of the included studies is detailed in Figure 2. The 
network for each outcome measure consisted of a subset of 
the presented network based on the availability of different 
outcomes within the 33 RCTs.
Trough FEV1 at 12 and 24 weeks
Changes in baseline trough FEV
1
 at 12 and 24 weeks were 
reported in a total of 24 and 19 trials, respectively. All inter-
ventions were found to be significantly better than placebo 
in terms of FEV
1
, at both 12 and 24 weeks.
Relative to placebo at 12 weeks, indacaterol 300 μg (dif-
ference: 0.167 L, 95% credible interval: [0.151, 0.183]) had 
the largest difference in change in baseline trough FEV
1
, 
followed by indacaterol 150 μg (0.163 L [0.148, 0.177]), 
indacaterol 75 μg (0.129 L [0.099, 0.157]), salmeterol 50 μg 
BID (0.105 L [0.085, 0.125]), vilanterol 25 μg OD (0.098 L 
[0.076, 0.120]), olodaterol 10 μg OD (0.083 [0.063, 0.103]), 
olodaterol 5 μg OD (0.073 [0.053, 0.092]), and formoterol 
12 μg BID (0.071 L [0.057, 0.085]; Figure 3A). Indacaterol 
300 μg OD and indacaterol 150 μg OD were associated with 
significantly better trough FEV
1
 compared to indacaterol 
75 μg OD, salmeterol 50 μg BID, vilanterol 25 μg OD, olo-
daterol 10 μg OD, olodaterol 5 μg OD, and formoterol 12 
μg BID, and were not statistically different from each other. 
Indacaterol 75 μg was associated with significantly better 
trough FEV
1
 compared to olodaterol 10 μg OD, olodaterol 5 
μg OD, and formoterol 12 μg BID. Salmeterol 50 μg BID was 
associated with significantly better trough FEV
1
 compared to 
olodaterol 5 μg OD and formoterol 12 μg BID. There were 
no significant differences between indacaterol 75 μg OD, 
salmeterol 50 μg BID, and vilanterol 25 μg OD.
Relative to placebo at 24 weeks, indacaterol 300 μg 
(0.162 L [0.143, 0.181]) had the largest difference in change 
in baseline trough FEV
1
, followed by indacaterol 150 μg 
(0.147 L [0.129, 0.164]), vilanterol 25 μg OD (0.094 L [0.065, 
0.124]), salmeterol 50 μg BID (0.082 L [0.066, 0.098]), 
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Figure 2 Network diagram of LABA monotherapy trials included in network meta-analysis.
Note: n=33 total randomized controlled trials.
Abbreviations: BID, twice daily; OD, once daily; LABA, long-acting beta agonist.
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olodaterol 10 μg OD (0.079 L [0.059, 0.099]), olodaterol 5 μg 
OD (0.074 [0.055, 0.094]), and formoterol 12 μg BID (0.061 
[0.046, 0.076]; Figure 3B). Indacaterol 75 μg OD was not 
included in the 24-week analysis. As in the 12-week analy-
sis, indacaterol 300 μg OD and indacaterol 150 μg OD were 
associated with significantly better trough FEV
1
 compared 
to vilanterol 25 μg OD, salmeterol 50 μg BID, olodaterol 10 
μg OD, olodaterol 5 μg OD, and formoterol 12 μg BID, and 
were not statistically different from each other (Table 2). In 
addition, vilanterol 25 μg OD had significantly higher mean 
trough FEV
1
 than formoterol 12 μg BID. No other significant 
differences were observed at 24 weeks.
TDI focal score at 12 and 24 weeks
Changes in baseline mean TDI focal scores at 12 and 24 weeks 
were reported in 14 and 15 trials, respectively. At 12 and 
24 weeks, all interventions were found to be significantly 
better than placebo. Relative to placebo at 12 weeks, inda-
caterol 300, 150, and 75 μg OD (1.171 [0.906, 1.401], 1.051 
[0.826, 1.291], and 0.831 [0.330, 1.336], respectively) had the 
highest difference in TDI focal scores at 12 weeks, followed 
by olodaterol 10 μg OD (0.734 [0.278, 1.166]), vilanterol 
25 μg OD (0.665 [0.284, 1.054]), olodaterol 5 μg OD (0.629 
[0.187, 1.058]), formoterol 12 μg BID (0.618 [0.281, 0.925]), 
and salmeterol 50 μg BID (0.555 [0.246, 0.887]; Figure 4A). 
Indacaterol 300 μg OD and indacaterol 150 μg OD were 
associated with significantly higher mean TDI focal score 
compared to salmeterol 50 μg BID and formoterol 12 μg BID. 
Indacaterol 300 μg OD was also associated with significantly 
higher mean TDI focal score compared to olodaterol 5 μg 
OD and vilanterol 25 μg OD (Table 3). No other significant 
differences were observed at 12 weeks.
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Figure 3 Change from baseline differences in trough FEV1 (L) for intervention versus placebo at 12 and 24 weeks. (A) Trough FEV1 at 12 weeks and (B) trough FEV1 at 
24 weeks.
Abbreviations: FeV1, forced expiratory volume in 1 second; FOR, formoterol; IND, indacaterol; OLO, olodaterol; SAL, salmeterol; VIL, vilanterol.
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Relative to placebo at 24 weeks, indacaterol 300 μg OD 
(1.184 [0.942, 1.433]) had the highest difference in TDI 
focal scores at 24 weeks, followed by indacaterol 150 μg OD 
(0.894 [0.653, 1.139]), salmeterol 50 μg BID (0.696 [0.423, 
0.965]), vilanterol 25 μg OD (0.693 [0.297, 1.093]), formot-
erol 12 μg BID (0.594 [0.359, 0.838]), olodaterol 5 μg OD 
(0.556 [0.143, 0.975), and olodaterol 10 μg OD (0.501 [0.097, 
0.920]; Figure 4B). Indacaterol 75 μg OD was not included in 
the 24-week analysis. Indacaterol 300 μg OD was associated 
with a significantly higher mean TDI focal score compared to 
all other LABAs (including indacaterol 150 μg OD; Table 3). 
No other significant differences were observed at 24 weeks.
sgrQ total score at 12 and 24 weeks
Changes from baseline in SGRQ total score at weeks 12 
and 24 were reported in a total of 14 and 16 trials, respec-
tively. At 12 and 24 weeks, all interventions were found to 
be significantly better than placebo. No significant differ-
ences were noted at 12 or 24 weeks between the different 
LABAs, except that indacaterol 150 μg was significantly 
better than salmeterol 50 μg BID (−1.776 [−3.430, −0.023]) 
at week 24 (Table 4).
Relative to placebo, the numerically best SGRQ 
scores at 12 weeks belonged to (in order) olodaterol 
10 μg OD (−4.144 [−6.089, −2.161]), indacaterol 150 μg 
(−4.022 [−5.096, −2.962]), indacaterol 300 μg (−3.704 
[−4.922, −2.501]), and indacaterol 75 μg OD (−3.691 
[−5.825, −1.509]), followed by formoterol 12 μg BID 
(−3.150 [−4.464, −1.890]), olodaterol 5 μg OD (−3.047 
[−5.014, −1.107]), and salmeterol 50 μg BID (−2.710 
[−4.463, −0.935]). For 24 weeks, the best scores belonged 
to olodaterol 10 μg OD (−3.589 [−5.704, −1.429]), inda-
caterol 150 μg OD (−3.155 [−4.504, −1.752]), and vilanterol 
25 μg OD (−2.906 [−5.042, −0.769]), followed by indacaterol 
300 μg OD (−2.843 [−4.321, −1.407]), formoterol 12 μg BID 
(−1.401 [−2.694, −0.113]), and salmeterol 50 μg BID (−1.379 
[−2.559, −0.286]; Figure 5). Vilanterol 25 μg OD was not 
included in the 12-week analysis, and indacaterol 75 μg OD 
was not included in the 24-week analysis.
Exacerbation rate
A total of 14 trials that reported the exacerbation rate were 
included in the evidence network including salmeterol 50 μg 
BID, formoterol 12 μg BID, indacaterol 150 μg OD, inda-
caterol 300 μg OD, olodaterol 5 μg OD, olodaterol 10 μg OD, 
and placebo. The exacerbation rates were significantly lower 
for salmeterol 50 μg BID, indacaterol 150 μg OD, and inda-
caterol 300 μg OD, compared with placebo. In addition, inda-
caterol 150 μg OD was significantly better than olodaterol 
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5 μg OD (0.773 [0.590, 0.991]) and olodaterol 10 μg OD 
(0.737 [0.565, 0.939]; Table 5 and Figure 6).
Sensitivity analysis for trough FEV1
A summary of the NMA results for trough FEV
1
 after adjust-
ing for female percentage, disease severity, ICS use, and the 
subgroup with no concomitant LAMA use at 12 and 24 weeks 
is presented in Figure 7. All the changes were minimal, 
ranging from −0.005 to 0.004 L for week 12 outcomes and 
from −0.006 to 0.012 L for week 24 outcomes, illustrating 
that the NMA results were robust.
Discussion
This study is the first NMA to analyze the comparative 
efficacy of all currently available LABAs, including the 
newer agents for the treatment of moderate to severe COPD. 
Thus, this study provides the most up-to-date understanding 
of the treatment landscape for COPD in terms of LABA 
monotherapies as well as the most complete comparative 
analysis of effective treatment options and dosages in terms 
of efficacy outcomes: FEV
1
, TDI focal score, SGRQ, and 
exacerbation rate. The results indicate that indacaterol was 
the most effective LABA monotherapy for the treatment of 
COPD, similar to the findings of earlier studies comparing 
LABA efficacy.23,24
Specifically, indacaterol 150 μg OD and indacaterol 
300 μg OD were associated with significant improve-
ment in 12- and 24-week trough FEV
1
 compared to all 
other LABAs, and indacaterol 75 μg OD was associated 
with significant improvement in trough FEV
1
 at week 12 
?
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Figure 4 Difference in change from baseline TDI focal score of intervention versus placebo at 12 and 24 weeks. (A) TDI focal score at 12 weeks and (B) TDI focal score 
at 24 weeks.
Abbreviations: FOR, formoterol; IND, indacaterol; OLO, olodaterol; SAL, salmeterol; TDI, transition dyspnea index; VIL, vilanterol; CFB, change from baseline.
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Figure 5 Change from baseline difference in SGRQ total score for intervention versus placebo at 12 and 24 weeks. (A) SGRQ total score at 12 weeks and (B) SGRQ total 
score at 24 weeks.
Abbreviations: FOR, formoterol; IND, indacaterol; OLO, olodaterol; PLBO, placebo; SAL, salmeterol; SGRQ, St George’s Respiratory Questionnaire; VIL, vilanterol.
Table 5 Results of random effect network meta-analysis for exacerbation rate
Comparators Interventions
IND 150 μg IND 300 μg
Rate ratio (95% CrI) P-value 
(better) %a
Rate ratio (95% CrI) P-value 
(better) %a
PlBO 0.729 (0.607, 0.866) .99 0.817 (0.692, 0.959) .99
sal 50 μg 0.895 (0.737, 1.089) 88 1.004 (0.834, 1.220) 52
FOr 12 μg 0.845 (0.657, 1.072) 93 0.945 (0.760, 1.159) 73
InD 150 μg n/a n/a 1.128 (0.909, 1.378) 13
InD 300 μg 0.897 (0.726, 1.100) 87 n/a n/a
OlO 5 μg 0.773 (0.590, 0.991) 98 0.865 (0.674, 1.094) 89
OlO 10 μg 0.737 (0.565, 0.939) .99 0.826 (0.645, 1.035) 96
Note: aP (better) denotes the probability that the intervention dose (column) is more effective than the comparator dose (row).
Abbreviations: 95% CrI, 95% credible interval; FOR, formoterol; IND, indacaterol; N/A, not applicable; OLO, olodaterol; PLBO, placebo; SAL, salmeterol.
compared to formoterol and olodaterol (both 5 and 10 μg 
doses). In addition, indacaterol, 300 μg in particular, showed 
statistical superiority over other LABAs in TDI score, and 
indacaterol 150 μg showed statistical superiority over olo-
daterol 5 μg and olodaterol 10 μg OD in exacerbation rates. 
Olodaterol 10 μg OD showed numerical superiority in SGRQ 
scores at 12 and 24 weeks, although the results were not 
statistically different from the other LABAs.
The outcomes compared in this meta-analysis each have 
valid thresholds for clinically relevant differences versus 
placebo. For example, for FEV
1
, a widely accepted thresh-
old, is a change of 100 mL from baseline; for TDI focal 
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Figure 6 Exacerbation rate (rate ratio) of intervention versus placebo.
Abbreviations: FOr, formoterol; InD, indacaterol; OlO, olodaterol; sal, salmeterol.
score, a $1 unit score reduction; for SGRQ total score, a 
reduction of 4 units; and for exacerbation rate, an annual 
rate reduction of 20%.49 These outcomes were used for the 
determination of efficacy against placebo in respective clini-
cal trials; however, the validity of using these thresholds for 
post hoc active-arm comparisons has not been empirically 
evaluated. Thus, NMAs such as the current analysis are useful 
for comparing active treatments by testing for statistically 
significant differences between treatment outcomes after 
showing clinically meaningful efficacy against placebo. 
Future prospective studies evaluating the thresholds for 
clinically meaningful differences between active treatments 
in COPD therapy trials are needed.
The results of this study add to and update the pre-existing 
literature on the comparative efficacy of LABAs in the treat-
ment of COPD, while coming to similar conclusions as previ-
ous studies about the efficacy of indacaterol. For example, 
a 2013 NMA on the comparative efficacy of long-acting 
bronchodilators for COPD found that indacaterol was associ-
ated with higher trough FEV
1
 and superior improvement in 
SGRQ score over comparative LABAs.23 In addition, a 2012 
comparative effectiveness study evaluated indacaterol for 
COPD versus placebo, formoterol, and salmeterol in RCTs 
using the outcomes trough FEV
1
, SGRQ, and TDI total 
scores. It found that indacaterol was as good as or superior 
to these bronchodilators in all the outcomes measured, and 
that indacaterol 300 μg resulted in the best overall efficacy.50 
A 2014 systematic review compared efficacy outcomes 
(FEV
1
, SGRQ and TDI scores, exacerbations, and use of 
rescue medication at 12 weeks) for olodaterol and indacaterol 
and determined that these drugs had similar efficacy.24 How-
ever, a comment published later in 2014 noted that the study 
suffered from several limitations including a restricted search 
date resulting in exclusion of relevant clinical trials, study 
design heterogeneity, and reliance on data from other NMAs 
rather than primary data within RCTs.51
In the current analysis, only trials of the inhalation pow-
der form of formoterol were included, in order to maintain 
consistency with the delivery device of the other compara-
tors. However, nebulized formoterol may be beneficial for 
patients who are unable to use inhalation powder for reasons 
including frailty, arthritis, visual impairment, compromised 
mental capacity, exacerbation, difficulty using an inhaler, or 
inadequate hand/breath coordination.
Important differences may exist between real-world 
practice and clinical trial populations, such as training for 
the use of inhalers, adherence to treatment, and routine 
medical care, all of which may limit the applicability of the 
current results. Some limitations inherent to NMAs apply 
to the results of this study. For example, although the tri-
als included in the NMA were of good caliber, the validity 
of the current findings depends on the quality, biases, and 
study and patient characteristic reporting consistency of the 
included RCTs. Some variation existed in their inclusion 
criteria regarding the concomitant use of LABA and ICSs, 
smoking history, age, the severity of COPD, and exacerbation 
history. Though sensitivity analyses have been conducted for 
our main outcome FEV
1
, meta-regression analyses of study-
level data can be prone to ecological bias (ie, the association 
between the study-level effect patient characteristics and 
treatment effects may not reflect the individual-level effect 
modification of a covariate). Thus, there is a risk of residual 
confounding bias. Since there was only a single head-to-head 
trial, the ability to check the consistency of the direct and 
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Figure 7 Sensitivity analysis for change from baseline in trough FEV1 (L). (A) Trough FEV1 at 12 weeks and (B) trough FEV1 at 24 weeks.
Abbreviations: FeV1, forced expiratory volume in 1 second; FOR, formoterol; ICS, inhaled corticosteroid; IND, indacaterol; LAMA, long-acting muscarinic antagonist; OLO, 
olodaterol; sal, salmeterol; VIl, vilanterol.
International Journal of COPD 2017:12 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
379
Network meta-analysis of long-acting β2-agonist monotherapies for COPD
indirect evidence was limited. However, in this head-to-head 
trial, indacaterol 150 μg was associated with a 0.06 L higher 
FEV
1
 compared to salmeterol 50 μg,19 which is consistent 
with the 0.057 L estimated in this analysis. In addition, other 
outcomes, which are important in the measurement of COPD 
treatment efficacy and safety and played an essential role in 
treatment decisions, such as the use of rescue treatments and 
the severity of exacerbations, were not assessed in this study. 
Future studies are warranted to further evaluate these out-
comes among different treatment options for COPD patients. 
Lastly, exacerbations were expected to be defined differently 
among the included studies, and the NMA results might be 
subject to those inconsistencies, if any. Because the number 
of studies that contained that study outcome (exacerbations) 
was small, no subgroup analysis was conducted in this study. 
Future research may be needed to conduct subgroup analysis 
among studies with consistent criteria and definitions, when 
there are sufficient studies.
Conclusion
In conclusion, indacaterol 300 μg OD, followed by 150 μg OD, 
and 75 μg OD, were the most effective LABA monotherapies 
for COPD in terms of trough FEV
1
 and TDI focal scores.
Acknowledgments
Medical writing assistance was provided by Shelley Batts, 
PhD, an employee of Analysis Group, Inc., with financial 
support from Novartis. We would like to thank Jenny Guo 
of Analysis Group for helping with part of the data analy-
sis and Noelle Thew of Analysis Group for helping audit 
the manuscript. Funding for this research was provided 
by Novartis. 
Author contributions
All authors had full access to all of the data in the study and 
take responsibility for the integrity of the data and accuracy of 
the data analysis. All authors contributed substantially to the 
study design, data analysis and interpretation, and the writing 
of the manuscript. The study sponsor was involved in all 
stages of the study research and manuscript preparation, but 
all authors participated in the design of the study and contrib-
uted to the manuscript development. Data were collected by 
Analysis Group and analyzed and interpreted in collaboration 
with all other authors. All the authors vouch for the accuracy 
and completeness of the data reported and the adherence of 
the study to the protocol, and all the authors made the deci-
sion to submit the manuscript for publication.
Disclosure
J-BG, PG, PA, and DLK are employees of Novartis and own 
stock/stock options. KAB, EXD, and JES are employees of 
Analysis Group Inc., which has received consultancy fees 
from Novartis. JFD is a member of the Data Safety Monitor-
ing Board for Novartis, AstraZeneca, Gilead, CSA Medical, 
and Insmed, and is a consultant to AstraZeneca, Sunovion, 
and GlaxoSmithKline. The authors report no other conflicts 
of interest in this work.
References
 1. Global Strategy for the Diagnosis, Management and Prevention 
of COPD, Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) 2016. (updated January 2016). Available from: http://www.
goldcopd.org/. Accessed April 7, 2016.
 2. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability 
(YLDs) for 1,160 sequelae of 289 diseases and injuries 1990–2010: 
a systematic analysis for the Global Burden of Disease Study 2010. 
Lancet. 2012;380(9859):2163–2196.
 3. Davis RM, Novotny TE. The epidemiology of cigarette smoking and its 
impact on chronic obstructive pulmonary disease. Am Rev Respir Dis. 
1989;140(3 Pt 2):S82–S84.
 4. Kojima S, Sakakibara H, Motani S, et al. Incidence of chronic obstruc-
tive pulmonary disease, and the relationship between age and smoking 
in a Japanese population. J Epidemiol. 2007;17(2):54–60.
 5. Schikowski T, Sugiri D, Ranft U, et al. Long-term air pollution exposure 
and living close to busy roads are associated with COPD in women. 
Respir Res. 2005;6:152.
 6. WHO. Chronic obstructive pulmonary disease (COPD); 2016. Available 
from: http://www.who.int/mediacentre/factsheets/fs315/en/. Accessed 
April 4, 2016.
 7. Celedon JC, Lange C, Raby BA, et al. The transforming growth factor-
beta1 (TGFB1) gene is associated with chronic obstructive pulmonary 
disease (COPD). Hum Mol Genet. 2004;13(15):1649–1656.
 8. Keatings VM, Cave SJ, Henry MJ, et al. A polymorphism in the tumor 
necrosis factor-alpha gene promoter region may predispose to a poor 
prognosis in COPD. Chest. 2000;118(4):971–975.
 9. Anzueto A, Sethi S, Martinez FJ. Exacerbations of chronic obstructive 
pulmonary disease. Proc Am Thorac Soc. 2007;4(7):554–564.
 10. Lopez-Campos JL, Tan W, Soriano JB. Global burden of COPD. 
Respirology. 2016;21(4):14–23.
 11. WHO. Household air pollution and health, Fact sheet #292; 2016. 
Available from: http://www.who.int/mediacentre/factsheets/fs292/en/. 
Accessed April 4, 2016.
 12. NIH-NHLB. Morbidity & mortality: 2012 chart book on cardiovascular, 
lung, and blood diseases; 2012. Available from: http://www.nhlbi.nih.
gov/resources/docs/2012_ChartBook_508.pdf. Accessed April 7, 2016.
 13. FDA Drug Safety Communication: new safety requirements for 
long-acting inhaled asthma medications called Long-Acting Beta-
Agonists (LABAs); 2010. Available from: http://www.fda.gov/Drugs/
DrugSafety/PostmarketDrugSafetyInformationforPatientsandProvid-
ers/ucm200776.htm. Accessed September 27, 2016.
 14. Cazzola M, Page C. Long-acting bronchodilators in COPD: where are 
we now and where are we going? Breathe. 2014;10(2):110–120.
 15. Dahl R, Chung KF, Buhl R, et al. Efficacy of a new once-daily long-
acting inhaled beta2-agonist indacaterol versus twice-daily formoterol 
in COPD. Thorax. 2010;65(6):473–479.
 16. Koch A, Pizzichini E, Hamilton A, et al. Lung function efficacy and 
symptomatic benefit of olodaterol once daily delivered via Respimat® 
versus placebo and formoterol twice daily in patients with GOLD 2–4 
COPD: results from two replicate 48-week studies. Int J Chron Obstruct 
Pulmon Dis. 2014;9:697–714.
International Journal of COPD 2017:12submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
380
Donohue et al
 17. Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, 
Church A. Efficacy and safety of once-daily umeclidinium/vilanterol 
62.5/25 mcg in COPD. Respir Med. 2013;107(10):1538–1546.
 18. Kornmann O, Dahl R, Centanni S, et al; INLIGHT-2 (Indacaterol 
Efficacy Evaluation Using 150-μg Doses with COPD Patients) study 
investigators. Once-daily indacaterol versus twice-daily salmeterol for 
COPD: a placebo-controlled comparison. Eur Respir J. 2011;37(2): 
273–279.
 19. Korn S, Kerwin E, Atis S, Amos C, Owen R, Lassen C; INSIST study 
group. Indacaterol once-daily provides superior efficacy to salmeterol 
twice-daily in COPD: a 12-week study. Respir Med. 2011;105(5): 
719–726.
 20. Ferguson GT, Feldman GJ, Hofbauer P, et al. Efficacy and safety of 
olodaterol once daily delivered via Respimat(R) in patients with GOLD 
2–4 COPD: results from two replicate 48-week studies. Int J Chron 
Obstruct Pulmon Dis. 2014;9:629–645.
 21. Celli B, Crater G, Kilbride S, et al. Once-daily umeclidinium/
vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest. 
2014;145(5):981–991.
 22. Maltais F, Singh S, Donald AC, et al. Effects of a combination of 
umeclidinium/vilanterol on exercise endurance in patients with chronic 
obstructive pulmonary disease: two randomized, double-blind clinical 
trials. Ther Adv Respir Dis. 2014;8(6):169–181.
 23. Cope S, Donohue JF, Jansen JP, et al. Comparative efficacy of long-
acting bronchodilators for COPD: a network meta-analysis. Respir Res. 
2013;14:100.
 24. Roskell NS, Anzueto A, Hamilton A, Disse B, Becker K. Once-daily 
long-acting beta-agonists for chronic obstructive pulmonary disease: an 
indirect comparison of olodaterol and indacaterol. Int J Chron Obstruct 
Pulmon Dis. 2014;9:813–824.
 25. Agusti A, de Teresa L, De Backer W, et al. A comparison of the efficacy 
and safety of once-daily fluticasone furoate/vilanterol with twice-daily 
fluticasone propionate/salmeterol in moderate to very severe COPD. 
Eur Respir J. 2014;43(3):763–772.
 26. Cope S, Capkun-Niggli G, Gale R, Jardim JR, Jansen JP. Comparative 
efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combina-
tions of formoterol + budesonide or salmeterol + fluticasone for the 
treatment of chronic obstructive pulmonary disease–a network meta-
analysis. Int J Chron Obstruct Pulm Dis. 2011;6:329–344.
 27. D’Urzo AD, Rennard SI, Kerwin EM, Mergel V, Leselbaum AR, 
Caracta CF; AUGMENT COPD study investigators. Efficacy and 
safety of fixed-dose combinations of aclidinium bromide/formoterol 
fumarate: the 24-week, randomized, placebo-controlled AUGMENT 
COPD study. Respir Res. 2014;15:123.
 28. Singh D, Jones PW, Bateman ED, et al. Efficacy and safety of acli-
dinium bromide/formoterol fumarate fixed-dose combinations com-
pared with individual components and placebo in patients with COPD 
(ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm 
Med. 2014;14:178.
 29. Yao W, Wang C, Zhong N, et al. Effect of once-daily indacaterol in 
a predominantly Chinese population with chronic obstructive pulmo-
nary disease: a 26-week Asia-Pacific study. Respirology. 2014;19(2): 
231–238.
 30. Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation 
with QVA149 versus single bronchodilator therapy: the SHINE study. 
Eur Respir J. 2013;42(6):1484–1494.
 31. Rossi A, Kristufek P, Levine BE, et al; Formoterol in Chronic Obstructive 
Pulmonary Disease (FICOPD) II Study Group. Comparison of the efficacy, 
tolerability, and safety of formoterol dry powder and oral, slow-release 
theophylline in the treatment of COPD. Chest. 2002;121(4):1058–1069.
 32. Gross NJ, Nelson HS, Lapidus RJ, et al. Efficacy and safety of formot-
erol fumarate delivered by nebulization to COPD patients. Respir Med. 
2008;102(2):189–197.
 33. Kinoshita M, Lee SH, Hang LW, et al. Efficacy and safety of indacaterol 
150 and 300 microg in chronic obstructive pulmonary disease patients 
from six Asian areas including Japan: a 12-week, placebo-controlled 
study. Respirology. 2012;17(2):379–389.
 34. Donohue JF, Fogarty C, Lotvall J, et al. Once-daily bronchodilators for 
chronic obstructive pulmonary disease: indacaterol versus tiotropium. 
Am J Respir Crit Care Med. 2010;182(2):155–162.
 35. Gotfried MH, Kerwin EM, Lawrence D, Lassen C, Kramer B. Efficacy 
of indacaterol 75 mug once-daily on dyspnea and health status: results 
of two double-blind, placebo-controlled 12-week studies. COPD. 2012; 
9(6):629–636.
 36. Kerwin EM, Gotfried MH, Lawrence D, Lassen C, Kramer B. Efficacy and 
tolerability of indacaterol 75 mug once daily in patients aged $40 years 
with chronic obstructive pulmonary disease: results from 2 double-blind, 
placebo-controlled 12-week studies. Clin Ther. 2011;33(12):1974–1984.
 37. Feldman G, Siler T, Prasad N, et al. Efficacy and safety of indacaterol 
150 microg once-daily in COPD: a double-blind, randomised, 12-week 
study. BMC Pulm Med. 2010;10:11.
 38. Stockley RA, Chopra N, Rice L. Addition of salmeterol to existing 
treatment in patients with COPD: a 12 month study. Thorax. 2006;61(2): 
122–128.
 39. Chapman KR, Arvidsson P, Chuchalin AG, et al. The addition of 
salmeterol 50 microg bid to anticholinergic treatment in patients with 
COPD: a randomized, placebo controlled trial. Chronic obstructive 
pulmonary disease. Can Respir J. 2002;9(3):178–185.
 40. Rutten-van Molken M, Roos B, Van Noord JA. An empirical com-
parison of the St George’s Respiratory Questionnaire (SGRQ) and the 
Chronic Respiratory Disease Questionnaire (CRQ) in a clinical trial 
setting. Thorax. 1999;54(11):995–1003.
 41. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone 
propionate and survival in chronic obstructive pulmonary disease. 
N Engl J Med. 2007;356(8):775–789.
 42. Jones PW, Anderson JA, Calverley PM, et al. Health status in the 
TORCH study of COPD: treatment efficacy and other determinants of 
change. Respir Res. 2011;12:71.
 43. Celli B, Halpin D, Hepburn R, Byrne N, Keating ET, Goldman M. 
Symptoms are an important outcome in chronic obstructive pulmonary 
disease clinical trials: results of a 3-month comparative study using 
the Breathlessness, Cough and Sputum Scale (BCSS). Respir Med. 
2003;97(Suppl A):S35–S43.
 44. Hanania NA, Darken P, Horstman D, et al. The efficacy and safety 
of fluticasone propionate (250 microg)/salmeterol (50 microg) com-
bined in the Diskus inhaler for the treatment of COPD. Chest. 2003; 
124(3):834–843.
 45. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and 
fluticasone in the treatment of chronic obstructive pulmonary disease: 
a randomised controlled trial. Lancet. 2003;361(9356):449–456.
 46. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone 
propionate and salmeterol combination delivered via the Diskus device 
in the treatment of chronic obstructive pulmonary disease. Am J Respir 
Crit Care Med. 2002;166(8):1084–1091.
 47. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. 
Health outcomes following treatment for six months with once daily 
tiotropium compared with twice daily salmeterol in patients with COPD. 
Thorax. 2003;58(5):399–404.
 48. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-
controlled study comparing lung function and health status changes 
in COPD patients treated with tiotropium or salmeterol. Chest. 2002; 
122(1):47–55.
 49. Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, 
Wedzicha JA. Minimal clinically important differences in pharmaco-
logical trials. Am J Respir Crit Care Med. 2014;189(3):250–255.
 50. Cope S, Capkun-Niggli G, Gale R, et al. Efficacy of once-daily indacaterol 
relative to alternative bronchodilators in COPD: a patient-level mixed 
treatment comparison. Value Health. 2012;15(3):524–533.
 51. Donohue JF. Systematic review comparing LABA, olodaterol, and 
indacaterol: limitations. Int J Chron Obstruct Pulmon Dis. 2014;9: 
1331–1333.
 52. Dahl R, Greefhorst LA, Nowak D, et al. Inhaled formoterol dry powder 
versus ipratropium bromide in chronic obstructive pulmonary disease. 
Am J Respir Crit Care Med. 2001;164:778–784.
International Journal of COPD
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal
The International Journal of COPD is an international, peer-reviewed 
journal of therapeutics and pharmacology focusing on concise rapid 
reporting of clinical studies and reviews in COPD. Special focus is given 
to the pathophysiological processes underlying the disease, intervention 
programs, patient focused education, and self management protocols. 
This journal is indexed on PubMed Central, MedLine and CAS. The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
International Journal of COPD 2017:12 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
381
Network meta-analysis of long-acting β2-agonist monotherapies for COPD
